

## FY00-FY05 CPMS Amphetamine Treatment Data Summary (#009-06)

Prepared by Liang Wu, Budget Evaluation Office

Based on data received in December 2005

**The following data include treatment episodes with all levels of amphetamines use (primary, secondary, and tertiary).**

◆ Percentage of treatment enrollments for primary amphetamines use increased over past six years among all A&D treatments, from 10.5% in FY00 to 16.7% in FY05. Amphetamines use (including methamphetamine) at any level as percentage of all A&D treatments increased as well, from 17.8% in FY00 to 25.3% in FY05.

Substance	FY00	FY01	FY02	FY03	FY04	FY05
Primary amphetamine use	10.5%	10.8%	13.4%	14.0%	13.6%	16.7%
Any level amphetamine use	17.8%	19.0%	22.6%	23.4%	23.0%	25.3%
All drug tx episodes	<b>16582</b>	<b>17490</b>	<b>17655</b>	<b>16894</b>	<b>14955</b>	<b>14313</b>

◆ Percentage of primary amphetamines use among all level of amphetamine uses in seeking treatment increased more than 6% in FY2005.

Amphetamine Use	FY00	FY01	FY02	FY03	FY04	FY05
Primary use	59.0%	57.2%	59.4%	59.7%	59.1%	65.8%
Secondary use	26.8%	27.9%	26.4%	26.3%	27.3%	22.2%
Tertiary use	14.2%	15.0%	14.3%	14.0%	13.5%	12.0%
All amphetamine episodes	<b>2958</b>	<b>3317</b>	<b>3994</b>	<b>3955</b>	<b>3438</b>	<b>3628</b>

◆ FY2002 had the highest number of unduplicated clients enrolled in treatment who reported amphetamine use at any level. Of total unduplicated clients treated in each year, the percentage of new amphetamine clients was declining, indicating that the percentage of returning clients (enrolled more than once in six years) was creeping up.

Client type	FY00	FY01	FY02	FY03	FY04	FY05
Total clients	2363	2532	3012	2999	2696	2915
New clients		2109	2363	2104	1858	1958
Returning clients		423	649	895	838	957
Percent of new clients	<b>Baseline</b>	<b>83%</b>	<b>78%</b>	<b>70%</b>	<b>69%</b>	<b>67%</b>

◆ Of 12,755 unduplicated clients (FY00-FY05), about 65% had one treatment, and 35% returned to the treatment at least one more time during the six years' period.

Number of client TX episodes	Frequency	Percent
1 tx episode	8339	65.4
2 tx episodes	2384	18.7
3 or more tx episodes	2032	15.9
<b>Total</b>	<b>12755</b>	<b>100</b>

◆ Of 12,755 unduplicated clients (FY00-FY05), 56.3% had at least one treatment associated with primary amphetamine use; 27.6% with secondary use, and 16.2% with tertiary use.

Drug choice	Frequency	Percent
At least 1 primary amphetamine use	7178	56.3
At least 1 secondary amphetamine use	3517	27.6
At least 1 tertiary amphetamine use	2060	16.2
<b>Total</b>	<b>12755</b>	<b>100</b>

**The following data only include treatment episodes that reported amphetamines as primary drug choice.**

◆ Percent of Hispanics enrolled in amphetamine treatment increased slightly over the past two years. There was a noticeable decrease over the years in percentage of White among all amphetamines treatment episodes.

Race/Ethnicity	FY00	FY01	FY02	FY03	FY04	FY05
White	88.3%	87.2%	88.7%	86.6%	81.7%	80.6%
Black	1.5%	2.4%	2.1%	2.2%	2.7%	2.8%
Native Amer.	7.0%	7.0%	4.4%	6.8%	7.9%	7.4%
Asian Amer.	0.9%	1.1%	0.5%	0.6%	1.2%	1.0%
Hispanic	1.7%	1.7%	2.4%	2.6%	4.3%	5.1%
Other	0.6%	0.6%	1.9%	1.1%	2.3%	3.1%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ In past six years, 45.8% of amphetamine treatment episodes were female, compared to 32.5% female among all treatment episodes between FY00 and FY2005. There was a disproportional female amphetamine episode among all A&D treatment.

Gender	FY00	FY01	FY02	FY03	FY04	FY05
Male	52.3%	56.1%	55.1%	53.9%	53.9%	53.7%
Female	47.7%	43.9%	44.9%	46.1%	46.1%	46.3%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ Percent of youth age 17 or under enrolled in amphetamines treatment increased over past five years, from 4.5% in FY00 to 9.6% in FY05.

Age	FY00	FY01	FY02	FY03	FY04	FY05
0-17	4.5%	4.9%	5.0%	5.3%	7.6%	9.6%
18-35	63.8%	65.5%	61.2%	59.8%	58.0%	58.3%
36 and over	31.6%	29.7%	33.7%	34.8%	34.4%	32.1%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ For those reporting amphetamines as primary drug choice, the average age of first-time use was 19.9. Native Americans and Hispanics started a little earlier in comparison with other race/ethnicity groups.

Race/Ethnicity	Average Age	Standard Deviation
White	20.0	7.3
Black	21.5	7.7
Native American	18.5	7.1
Asian American	20.5	6.6
Hispanic	18.8	6.9
<b>Overall</b>	<b>19.9</b>	<b>7.3</b>

◆ The following table shows the frequency of amphetamine use as a primary substance (excluding ‘not in use’ category). The percentage of daily use (1 or more time a day) didn’t change much over the years.

Frequency	FY00	FY01	FY02	FY03	FY04	FY05
Less than once a week	8.8%	9.6%	11.0%	9.5%	8.4%	8.5%
Once a week	3.6%	4.8%	4.9%	5.1%	4.2%	4.0%
2-4 times a week	16.8%	19.6%	19.0%	19.0%	19.6%	18.2%
Once daily	11.0%	9.6%	10.6%	11.0%	15.7%	16.5%
2-3 times a day	26.3%	28.9%	25.9%	25.0%	23.1%	20.2%
4 or more times a day	33.5%	27.5%	28.7%	30.3%	29.0	31.1%
<b>Total</b>	<b>1689</b>	<b>1818</b>	<b>2274</b>	<b>2195</b>	<b>1893</b>	<b>2167</b>

	FY00	FY01	FY02	FY03	FY04	FY05
Mean severity score	4.43	4.26	4.21	4.28	4.28	4.28
<b>Total Tx episodes</b>	<b>1689</b>	<b>1818</b>	<b>2274</b>	<b>2195</b>	<b>1893</b>	<b>2167</b>

◆ Only 18% percent of primary amphetamine treatment episodes used amphetamines exclusively. About 82% were multiple A&D users.

Drug choice	Frequency	Percent
Amphetamine only	3879	18.2
Amphetamine plus 1 other A&D use	6378	30.0
Amphetamine plus 2 other A&D use	11033	51.8
<b>Total</b>	<b>21290</b>	<b>100</b>

◆ For primary amphetamine treatment episodes, the route of admission have changed significantly: injection was down from 44% in FY00 to 29.2% in FY05 and smoke was up from 23.4% in FY00 to 53.2% in FY05.

Route of admission	FY00	FY01	FY02	FY03	FY04	FY05
Inject	44.0%	41.1%	37.7%	35.8%	32.9%	29.2%
Smoke	23.4%	28.2%	34.8%	40.4%	47.5%	53.2%
Inhale	27.7%	25.1%	22.4%	19.2%	15.2%	13.8%
Oral	4.7%	5.0%	4.3%	3.3%	3.4%	3.0%
Other	0.3%	0.6%	0.5%	0.3%	0.3%	0.3%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ Proportions of amphetamine treatment referral source vary from year to year. Overall, referrals from local or State agencies and criminal justice system account for two-third of Amphetamine related treatment episodes.

Referral source	FY00	FY01	FY02	FY03	FY04	FY05
A&D treatment agencies	9.7%	13.3%	14.0%	14.2%	12.0%	11.7%
Local or State agencies	18.8%	14.6%	13.2%	12.1%	16.8%	20.1%
Criminal justice system	46.7%	51.4%	51.5%	53.7%	50.7%	46.4%
Non-system	20.8%	16.5%	16.9%	15.4%	16.0%	17.7%
Other	3.9%	4.2%	4.4%	4.6%	4.6%	4.2%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ Majority of amphetamine clients had arrest history prior to treatment admission.

Insurance status	FY00	FY01	FY02	FY03	FY04	FY05
No arrest	27.1%	22.2%	23.5%	24.0%	27.3%	27.1%
1-3 arrests	44.2%	44.7%	44.8%	41.1%	38.1%	40.0%
4-10 arrest	22.8%	26.5%	26.2%	27.9%	26.8%	25.4%
11 or more arrests	5.9%	6.6%	5.5%	7.0%	7.9%	7.6%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ For the past two years, more amphetamine treatment clients were admitted without any health insurance. Percent of clients who had private health insurance increased in FY05.

Insurance status	FY00	FY01	FY02	FY03	FY04	FY05
Public insurance	58.4%	56.6%	66.0%	66.9%	49.5%	44.3%
Private insurance	3.5%	4.4%	4.6%	4.1%	3.5%	5.5%
No insurance	38.1%	38.9%	29.4%	29.0%	47.0%	50.1%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ The percentage of amphetamine episodes enrolled in residential treatment increased over the years while the outpatient enrollments dropped.

Tx modality	FY00	FY01	FY02	FY03	FY04	FY05
Residential	14.7%	15.4%	14.4%	20.4%	22.3%	23.9%
Outpatient	75.7%	75.7%	78.1%	71.1%	69.0%	68.6%
Other	9.6%	8.9%	7.6%	8.5%	8.7%	7.5%
<b>Total</b>	<b>1746</b>	<b>1896</b>	<b>2371</b>	<b>2360</b>	<b>2033</b>	<b>2388</b>

◆ For those exited from the treatment, the average length of stay was 83.4 days. Approximately one-third of episodes had a length of stay for more than three months before treatment ended.

Days from enrollment to exit	FY00	FY01	FY02	FY03	FY04	FY05*
1-7 days	22.7%	32.5%	34.1%	29.4%	29.1%	28.8%
8-30 days	17.7%	15.7%	13.2%	15.4%	14.7%	17.7%
31-90 days	23.1%	20.7%	18.6%	21.9%	19.2%	20.4%
>90 days	36.5%	31.0%	34.1%	33.3%	37.0%	33.1%
<b>Total</b>	<b>1589</b>	<b>1736</b>	<b>2182</b>	<b>2296</b>	<b>1891</b>	<b>1786</b>

*\*Statistics for FY05 Treatment duration & exit status could change upon receiving new data updates.*

◆ Of all closed treatment episodes, about one-third completed the treatment successfully. The neutral termination status includes close reasons such as ‘moved out of service area’, ‘further treatment is not appropriate’, and treatment ended due to program cut/reduction.

Exit status	FY00	FY01	FY02	FY03	FY04	FY05*
Successful	33.9%	32.3%	31.5%	35.3%	32.7%	35.3%
Unsuccessful	43.2%	34.2%	34.2%	36.0%	38.2%	40.5%
Neutral	22.9%	33.5%	34.3%	28.7%	29.1%	24.1%
<b>Total</b>	<b>1589</b>	<b>1736</b>	<b>2182</b>	<b>2296</b>	<b>1891</b>	<b>1786</b>

*\*Statistics for FY05 Treatment duration & exit status could change upon receiving new data updates.*